Loading data for HQL — first visit, this takes a few seconds.
Abrdn Life Sciences Inves... (HQL)
NYSE: HQL
· Real-Time Price · USD
22.34
+0.62 (2.85%)
At close: Aug 18, 2026, 3:59 PM
Abrdn Life Sciences Investors (HQL) Stock Price, Analysis & Data
2.85% (1D)
| Bid | 22.21 |
| Market Cap | 677.19M |
| Revenue (ttm) | 1.11M |
| Net Income (ttm) | 198.17M |
| Beta | 0.71 |
| EPS (ttm) | 6.64 |
| PE Ratio (ttm) | 3.35 |
| Forward PE | n/a |
| P/B (ttm) | 1.21 |
| P/S (ttm) | 610.21 |
| Earnings Date | n/a |
| Ask | 22.36 |
| Volume | 160,756 |
| Avg. Volume (20D) | 142,743 |
| Open | 21.93 |
| Previous Close | 21.72 |
| Day's Range | 21.93 - 22.45 |
| 52-Week Range | 13.57 - 22.45 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $2.24 (10.31%) |
| Ex-Dividend Date | Aug 24, 2026 |
About HQL
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture...
Industry Asset Management
Sector Financial Services
IPO Date May 1, 1992
Employees n/a
Stock Exchange NYSE
Ticker Symbol HQL
Financial Performance
In 2025, Abrdn Life Sciences Investors's revenue was 86.39M, a decrease of -0.35% compared to the previous year's 86.69M. Earnings were 85.59M, an increase of 0.35%.
Financial Statements